IRRITABLE BOWEL SYNDROME - PATHOGENESIS, EPIDEMIOLOGY, TREATMENT
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5401Keywords:
IBS, Irritable Bowel Syndrome, Gut-BrainAbstract
Irritable bowel syndrome (IBS) is a common disorder of gut–brain interaction characterized by recurrent abdominal pain and altered bowel habits, including diarrhea, constipation, or mixed patterns. Despite its significant impact on quality of life and healthcare systems, IBS remains underdiagnosed. Diagnosis is based on the Rome IV criteria, which emphasize symptom patterns rather than structural abnormalities. The pathogenesis of IBS is multifactorial and not fully understood, involving low-grade intestinal inflammation, immune activation, alterations in the gut microbiota, and dysregulation of the gut–brain axis, as well as psychological factors such as stress, anxiety, and depression. Epidemiological data show substantial global variation in IBS prevalence, influenced by geographic, methodological, and diagnostic differences. Recent meta-analyses estimate a global prevalence of approximately 14%, with higher rates observed in women and individuals experiencing psychological distress. Post-infectious IBS is also increasingly recognized, with a significantly elevated risk following acute gastroenteritis. Management of IBS requires a multidisciplinary and individualized approach. First-line strategies include patient education, dietary modifications, and stress management. Pharmacological treatments are selected based on the predominant symptom subtype, with options including antibiotics such as rifaximin for IBS-D and laxatives or secretagogues for IBS-C. Increasing attention has been given to microbiota-targeted therapies, including probiotics and fecal microbiota transplantation. Dietary interventions, particularly the low FODMAP diet, have shown effectiveness in reducing global IBS symptoms, although long-term adherence requires careful supervision. Overall, advances in research and treatment strategies offer promising prospects for improving symptom control, patient outcomes, and disease awareness.
References
Patel, N., & Shackelford, K. B. (2022). Irritable bowel syndrome. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK534810/
Galica, A. N., Galica, R., & Dumitrașcu, D. L. (2022). Diet, fibers, and probiotics for irritable bowel syndrome. Journal of Medicine and Life, 15(2), 174–179. https://doi.org/10.25122/jml-2022-0028
Sperber, A. D. (2021). Epidemiology and burden of irritable bowel syndrome: An international perspective. Gastroenterology Clinics of North America, 50(3), 489–503. https://doi.org/10.1016/j.gtc.2021.04.001
Long, Y., Huang, Z., Deng, Y., Chu, H., Zheng, X., Yang, J., Zhu, Y., Fried, M., Fox, M., & Dai, N. (2017). Prevalence and risk factors for functional bowel disorders in South China: A population-based study using the Rome III criteria. Neurogastroenterology & Motility, 29(1). https://doi.org/10.1111/nmo.12897
Huang, K. Y., Wang, F. Y., Lv, M., Ma, X. X., Tang, X. D., & Lv, L. (2023). Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World Journal of Gastroenterology, 29(26), 4120–4135. https://doi.org/10.3748/wjg.v29.i26.4120
Rahman, M. M., Mahadeva, S., & Ghoshal, U. C. (2017). Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World Journal of Gastroenterology, 23, 6788–6801. https://doi.org/10.3748/wjg.v23.i37.6788
Sperber, A. D. (2021). Epidemiology and burden of irritable bowel syndrome: An international perspective. Gastroenterology Clinics of North America, 50(3), 489–503. https://doi.org/10.1016/j.gtc.2021.04.001
Galica, A. N., Galica, R., & Dumitrașcu, D. L. (2021). Epidemiology of irritable bowel syndrome in Albania. Journal of Gastrointestinal and Liver Diseases, 30, 334–338. https://doi.org/10.15403/jgld-3828
Kovács, D. B., Szekely, A., Hubai, A. G., & Palsson, O. (2022). Prevalence, epidemiology and associated healthcare burden of Rome IV irritable bowel syndrome and functional dyspepsia in the adult population of Gibraltar. BMJ Open Gastroenterology, 9(1), e000979. https://doi.org/10.1136/bmjgast-2022-000979
Huang, K. Y., Wang, F. Y., Lv, M., Ma, X. X., Tang, X. D., & Lv, L. (2023). Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World Journal of Gastroenterology, 29(26), 4120–4135. https://doi.org/10.3748/wjg.v29.i26.4120
Arif, T. B., Ali, S. H., Bhojwani, K. D., Sadiq, M., Siddiqui, A. A., Ur-Rahman, A., Khan, M. Z., Hasan, F., & Shahzil, M. (2025). Global prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: A meta-analysis. European Journal of Gastroenterology & Hepatology, 37(12), 1314–1325. https://doi.org/10.1097/MEG.0000000000002994
Porcari, S., Ingrosso, M. R., Maida, M., et al. (2024). Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: Systematic review and meta-analysis. Gut, 73, 1431–1440. https://doi.org/10.1136/gutjnl-2023-331835
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021). ACG clinical guideline: Management of irritable bowel syndrome. The American Journal of Gastroenterology, 116(1), 17–44. https://doi.org/10.14309/ajg.0000000000001036
Cremon, C., Stanghellini, V., Barbaro, M. R., Cogliandro, R. F., Bellacosa, L., Santos, J., Vicario, M., Pigrau, M., Alonso Cotoner, C., Lobo, B., Azpiroz, F., Bruley des Varannes, S., Neunlist, M., DeFilippis, D., Iuvone, T., Petrosino, S., Di Marzo, V., & Barbara, G. (2017). Randomised clinical trial: The analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 45(7), 909–922. https://doi.org/10.1111/apt.13958
O’Sullivan, M., Clayton, N., Breslin, N. P., et al. (2000). Increased mast cells in the irritable bowel syndrome. Neurogastroenterology & Motility, 12(5), 449–457. https://doi.org/10.1046/j.1365-2982.2000.00221.x
Törnblom, H., Lindberg, G., Nyberg, B., & Veress, B. (2002). Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology, 123(6), 1972–1979. https://doi.org/10.1053/gast.2002.37059
Ohman, L., Lindmark, A. C., Isaksson, S., Posserud, I., Strid, H., Sjövall, H., & Simrén, M. (2009). B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterology & Motility, 21(6), 644–650.e27. https://doi.org/10.1111/j.1365-2982.2009.01272.x
Foley, S., Garsed, K., Singh, G., Duroudier, N. P., Swan, C., Hall, I. P., Zaitoun, A., Bennett, A., Marsden, C., Holmes, G., Walls, A., & Spiller, R. C. (2011). Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology, 140(5), 1434–1443.e1. https://doi.org/10.1053/j.gastro.2011.01.052
Singh, M., Singh, V., Schurman, J. V., Colombo, J. M., & Friesen, C. A. (2020). The relationship between mucosal inflammatory cells, specific symptoms, and psychological functioning in youth with irritable bowel syndrome. Scientific Reports, 10(1), 11988. https://doi.org/10.1038/s41598-020-68961-9
Desbonnet, L., Garrett, L., Clarke, G., Bienenstock, J., & Dinan, T. G. (2008). The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. Journal of Psychiatric Research, 43, 164–174. https://doi.org/10.1016/j.jpsychires.2008.03.009
Burns, G. L., Talley, N. J., & Keely, S. (2022). Immune responses in the irritable bowel syndromes: Time to consider the small intestine. BMC Medicine, 20(1), 115. https://doi.org/10.1186/s12916-022-02301-8
Nathani, R. R., Sodhani, S., & Goosenberg, E. (2025). Irritable bowel syndrome. StatPearls Publishing.
Black, C. J., Drossman, D. A., Talley, N. J., Ruddy, J., & Ford, A. C. (2020). Functional gastrointestinal disorders: Advances in understanding and management. The Lancet. https://doi.org/10.1016/S0140-6736(20)32115-2
Bear, T. L. K., Dalziel, J. E., Coad, J., Roy, N. C., Butts, C. A., & Gopal, P. K. (2020). The role of the gut microbiota in dietary interventions for depression and anxiety. Advances in Nutrition, 11, 890–907. https://doi.org/10.1093/advances/nmaa016
Xu, F., Fu, Y., Sun, T. Y., Jiang, Z., Miao, Z., Shuai, M., Gou, W., Ling, C., Yang, J., Wang, J., et al. (2020). The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for complex human diseases. Microbiome, 8, 145. https://doi.org/10.1186/s40168-020-00923-9
Weersma, R. K., Zhernakova, A., & Fu, J. (2020). Interaction between drugs and the gut microbiome. Gut, 69, 1510–1519. https://doi.org/10.1136/gutjnl-2019-320204
Rothschild, D., Weissbrod, O., Barkan, E., Kurilshikov, A., Korem, T., Zeevi, D., Costea, P. I., Godneva, A., Kalka, I. N., Bar, N., et al. (2018). Environment dominates over host genetics in shaping human gut microbiota. Nature, 555, 210–215. https://doi.org/10.1038/nature25973
Karakan, T., Ozkul, C., Küpeli Akkol, E., Bilici, S., Sobarzo-Sánchez, E., & Capasso, R. (2021). Gut-brain-microbiota axis: Antibiotics and functional gastrointestinal disorders. Nutrients, 13(2), 389. https://doi.org/10.3390/nu13020389
Lacy, B. E., Weiser, K., & De Lee, R. (2009). Review: The treatment of irritable bowel syndrome. Therapeutic Advances in Gastroenterology, 2(4), 221–238. https://doi.org/10.1177/1756283X09104794
Bonetto, S., Fagoonee, S., Battaglia, E., et al. (2021). Recent advances in the treatment of irritable bowel syndrome. Polish Archives of Internal Medicine, 131, 709–715. https://doi.org/10.20452/pamw.16067
Adriani, A., Ribaldone, D. G., Astegiano, M., Durazzo, M., Saracco, G. M., & Pellicano, R. (2018). Irritable bowel syndrome: The clinical approach. Panminerva Medica, 60(4), 213–222. https://doi.org/10.23736/S0031-0808.18.03541-3
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., Forbes, W. P., & TARGET Study Group. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. The New England Journal of Medicine, 364(1), 22–32. https://doi.org/10.1056/NEJMoa1004409
Pasta, A., Formisano, E., Calabrese, F., Plaz Torres, M. C., Bodini, G., Marabotto, E., Pisciotta, L., Giannini, E. G., & Furnari, M. (2024). Food intolerances, food allergies and IBS: Lights and shadows. Nutrients, 16(2), 265. https://doi.org/10.3390/nu16020265
Lenhart, A., & Chey, W. D. (2017). A systematic review of the effects of polyols on gastrointestinal health and irritable bowel syndrome. Advances in Nutrition, 8(4), 587–596. https://doi.org/10.3945/an.117.015560
Spiller, R. (2017). How do FODMAPs work? Journal of Gastroenterology and Hepatology, 32(Suppl. 1), 36–39. https://doi.org/10.1111/jgh.13694
Dionne, J., Ford, A. C., Yuan, Y., et al. (2018). A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAP diet in treating symptoms of IBS. The American Journal of Gastroenterology, 113, 1290–1300.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dominika Walczak, Karolina Niewola, Kamil Arciszewski, Natalia Hariasz , Karolina Orda, Jakub Szumiło, Klaudia Kasperska, Mariana Markiv, Michał Słowik, Paweł Stenzel
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
